Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Vanderbilt University Medical Center: Clinical Trials & FDA Approval Profile

Vanderbilt University Medical Center (Global / Institutional) sponsors 81 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 35 active protocols (20 recruiting now), 32 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.3%
Median Closed Enrollment vs National (145 pts)36 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Vanderbilt University Medical Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)81
Active Pipeline (Recruiting Now)35 (20)
Completed vs Stopped Early32 / 14 (17.3%)
Median Closed Actual Enrollment36 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Vanderbilt University Medical Center
Hospital Research SiteLocationShared Protocols
Vanderbilt University Medical CenterNashville, TN70
University of Mississippi Medical CenterJackson, MS3
UC Davis Comprehensive Cancer CenterSacramento, CA2

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vanderbilt University Medical Center across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Vanderbilt University Medical Center Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI